Chemical Structure (Anzupgo 01)
Anzupgo Cream
Product Images NDC 50222-280
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anzupgo (NDC 50222-280). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Leo Pharma, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Anzupgo 02)
Figure 1 (Anzupgo 03)
This text shows the percentage of responders for Delgocitinib 20 mg/g compared to the vehicle group, based on a sample size of 313 for Delgocitinib and 159 for the vehicle.*
Figure 2 (Anzupgo 04)
Figure 2 (Anzupgo 05)
This text provides information regarding the number of responders at a certain dosage of Delgocitini (20 mg/g). There were 309 responders in this group, while there were 156 responders in the vehicle group (control group).*
Figure 3 (Anzupgo 06)
Figure 3 (Anzupgo 07)
Principal Display Panel (30 g Tube Carton)
Anzupgo cream 2% is a topical cream for use on the hands and wrists. It should be applied twice daily to affected areas. The cream contains ingredients such as hydroxyanisole, cetostearyl alcohol, and citric acid monohydrate. It is important to store Anzupgo between 20°C to 25°C and not freeze it. This product is manufactured by LEQ Laboratories Ltd. in Ireland and distributed by LEO Pharma Inc. in the USA. Be sure to consult the prescribing information before use.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
